Home
Archive for
March 2015
Facebook Launches Suicide Prevention Initiative - WSJ video
Facebook is partnering with suicide prevention organizations on a new tool to identify people in distress. Forefront research scientist Ursula Whiteside discusses the project with Sara Murray.
"A life is like a garden. Perfect moments can be had, but not preserved, except in memory"
A life is like a garden. Perfect moments can be had, but not preserved, except in memory. LLAP
— Leonard Nimoy (@TheRealNimoy) February 23, 2015Don't smoke. I did. Wish I never had. LLAP
— Leonard Nimoy (@TheRealNimoy) January 11, 2015Most cancers caused by "bad luck" in cell division and "poor repair" of the defect
Researchers at Johns Hopkins University studied 31 different cancers. Of those, just 9 were found to be linked to bad genetics or unhealthy lifestyle choices. However, researchers excluded two of the most common cancers from their study, breast cancer and prostate cancer (published in the journal Science).
The most common cause of the production of most cancerous cells occurs when one chemical letter in DNA is incorrectly swapped for another during stem cell division. Scientists found that cancer rates were higher in parts of the body where cells are quickest to regenerate, thereby creating more random mutations.
Genetic mutations that randomly crop up as our stem cells divide are “the major contributors to cancer overall, often more important than either hereditary or external environmental factors.”
BBC: New research suggests most types of cancer are the result of bad luck, rather than unhealthy lifestyles, diet or even inherited genes.
References:
Study concludes that many cancers caused by bad luck in cell division | Fox News http://buff.ly/1xebIsy
Besides Lifestyle and Inherited Genes, Cancer Risk Also Tied to Bad Luck - WSJ http://buff.ly/1xebVMw
The most common cause of the production of most cancerous cells occurs when one chemical letter in DNA is incorrectly swapped for another during stem cell division. Scientists found that cancer rates were higher in parts of the body where cells are quickest to regenerate, thereby creating more random mutations.
Genetic mutations that randomly crop up as our stem cells divide are “the major contributors to cancer overall, often more important than either hereditary or external environmental factors.”
BBC: New research suggests most types of cancer are the result of bad luck, rather than unhealthy lifestyles, diet or even inherited genes.
References:
Study concludes that many cancers caused by bad luck in cell division | Fox News http://buff.ly/1xebIsy
Besides Lifestyle and Inherited Genes, Cancer Risk Also Tied to Bad Luck - WSJ http://buff.ly/1xebVMw
Ironstrength, the Doctor's Total-Body Exercise Routine - New York Times video
Dr. Jordan Metzl is a sports medicine physician who developed an extreme total-body workout routine called Ironstrength. He now teaches free exercise classes all around New York City. Produced by: Colin Archdeacon.
Myelodysplastic Syndromes / Myeloproliferative Disorders
What are myelodysplastic syndromes?
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterized by ineffective hemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukemia in a third of patients.
Who is affected?
15% of cases occur after chemotherapy or radiotherapy for a previous cancer. The syndromes are most common in elderly people.
What is the cause?
The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages.
What are the symptoms?
Clinical manifestations result from cytopenias (anemia, infection, and bleeding).
How to make the diagnosis?
Diagnosis is based on examination of blood and bone marrow showing blood cytopenias and hypercellular marrow with dysplasia, with or without excess of blasts. Prognosis depends largely on the marrow blast percentage, number and extent of cytopenias, and cytogenetic abnormalities.
What is the treatment?
Treatment of patients with lower-risk myelodysplastic syndromes, especially for anaemia, includes growth factors, lenalidomide, and transfusions.
Treatment of higher-risk patients is with hypomethylating agents and, whenever possible, allogeneic stem-cell transplantation.
In this first video in the series, Myeloproliferative Neoplasms 2015 - Mayo Clinic, Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses the treatment and management of myeloproliferative neoplasms as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.
Here is the complete playlist:
https://www.youtube.com/playlist?list=PLSWR1ylG_6JZKr0ChD4N_8MJ3g3FnF08S
References:
Myelodysplastic syndromes : The Lancet http://buff.ly/VwiRor
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterized by ineffective hemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukemia in a third of patients.
Who is affected?
15% of cases occur after chemotherapy or radiotherapy for a previous cancer. The syndromes are most common in elderly people.
What is the cause?
The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages.
What are the symptoms?
Clinical manifestations result from cytopenias (anemia, infection, and bleeding).
How to make the diagnosis?
Diagnosis is based on examination of blood and bone marrow showing blood cytopenias and hypercellular marrow with dysplasia, with or without excess of blasts. Prognosis depends largely on the marrow blast percentage, number and extent of cytopenias, and cytogenetic abnormalities.
What is the treatment?
Treatment of patients with lower-risk myelodysplastic syndromes, especially for anaemia, includes growth factors, lenalidomide, and transfusions.
Treatment of higher-risk patients is with hypomethylating agents and, whenever possible, allogeneic stem-cell transplantation.
In this first video in the series, Myeloproliferative Neoplasms 2015 - Mayo Clinic, Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses the treatment and management of myeloproliferative neoplasms as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.
Here is the complete playlist:
https://www.youtube.com/playlist?list=PLSWR1ylG_6JZKr0ChD4N_8MJ3g3FnF08S
References:
Myelodysplastic syndromes : The Lancet http://buff.ly/VwiRor
Subscribe to:
Posts
(
Atom
)